Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)

-arrhythmic drugs (AADs), 2) use of medication for rate control (beta blocker, calcium channel blocker and digoxin) and 3) use of anticoagulation agents (warfarin, coumadin, an NOAC)

stroke
beta-adrenergic blocking agents
antiarrhythmic drug
warfarin
digoxin
  • 0 views
  • 24 Feb, 2022
  • 1 location
Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction

years. The basic cohort - the subjects with the newly indicated indication for use: NOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors

  • 0 views
  • 21 Apr, 2022
  • 1 location
NOACs Use in AF or VTE (SUNSHINE Registry)

The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional inpatient/outpatient disease registry to assess the utilization of Non-vitamin k antagonist oral anticoagulants (NOACs), and associated outcomes. The SUNSHINE registry will focus on the collection …

holter monitor
vitamin k
electrocardiogram
blood clot
thromboembolism
  • 0 views
  • 19 Jun, 2022
  • 1 location
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment (PROFILE)

Prostate cancer is now the commonest cancer in men in the Western world, with over 49,000 new cases diagnosed each year and a lifetime risk of 1 in 11 in the United Kingdom. Prostate cancer (PrCa) can run in some families and research studies have identified several genetic changes in …

prostate cancer screening
prostate specific antigen
Accepts healthy volunteers
  • 1 views
  • 25 Apr, 2022
  • 1 location
Monitoring of NOAC Therapy: Standardizing Reference Intervals

This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.

Accepts healthy volunteers
  • 0 views
  • 07 Jun, 2022
  • 1 location
Long Term Outcomes of Venous Thromboembolism

This prospective observational follow-up study is designed to assess the long-term outcomes after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant (NOAC

rivaroxaban
dvts
noac
anticoagulants
blood clot
  • 26 views
  • 21 Jan, 2021
  • 3 locations
Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome

), availability of novel oral anticoagulants (NOAC), the natural course of disease can be changed with good outcomes. [12] Standard Coagulation tests (SCTs) like PT, aPTT, and platelet count are not predictive of

platelet count
thromboelastography
clot
thrombophilia
blood clot
  • 0 views
  • 25 Nov, 2021
  • 1 location
Lifetech LAmbre Left Atrial Appendage Closure System Post-Market Registry

Single-center, single-arm, prospective, post-market study of LAmbre LAA Closure System. To evaluate immediate and long term procedural success of Lifetech LAmbre occluders in patients.

fibrillation
permanent atrial fibrillation
left atrial appendage closure
  • 0 views
  • 21 May, 2021
  • 1 location
Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)

The objective of this registry is the characterization of patients with atrial fibrillation (AF) and/ or atrial flutter (AFL) with confirmed VHD who are prescribed edoxaban in a real life clinical setting.

stroke
edoxaban
atrial flutter
fibrillation
anticoagulation therapy
  • 6 views
  • 21 Mar, 2022
  • 10 locations
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study (PROTECT_AR)

The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial arrhythmias (AA)

arrhythmia
apixaban
thromboembolism
  • 4 views
  • 09 Feb, 2022
  • 8 locations